ZYNE stock forecast
Our latest prediction for Zynerba Pharmaceuticals, Inc.'s stock price was made on the Aug. 6, 2018 when the stock price was at 6.13$.
In the short term (2weeks), ZYNE's stock price should outperform the market by 6.10%. During that period the price should oscillate between -9.25% and +19.17%.
In the medium term (3months), ZYNE's stock price should outperform the market by 7.30%. During that period the price should oscillate between -20.68% and +41.14%.Get email alerts
About Zynerba Pharmaceuticals, Inc.
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. It engages in the development and commercialization of transdermal pharmaceutically-produced cannabinoid treatments for rare and near-rare neurological and psychiatric, or neuropsychiatric, disorders in patients with high unmet medical needs. The company was founded by Audra L. Stinchcomb on January 31, 2007 and is headquartered in Devon, PA.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -2.82$ per share.
The book value per share is 2.27$
Three months stock forecastAug. 6, 2018
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|